A single protein may be holding back CAR T cancer therapy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their cancer-fighting power over time. When NFIL3 was disabled, the cells remained stronger for longer and co
